. 2020 Feb 13;13(2):352–361. doi: 10.1111/cts.12719

Table 3.

Comparison between brand and generic dabigatran with less extreme systemic exposure

Treatment strategy	Therapies in ascending order of QALY
	Cost		QALY		Stroke, N	All bleeding, N		Dominance
	Absolute	Incremental	Absolute	Incremental	Stroke, N	Minor bleeding, N	Major bleeding, N	Dominance
Generic dabigatran (F = 1.125)	$50,089	Ref	7.34	Ref	2,214	13,167		Absolutely dominated
Generic dabigatran (F = 1.125)	$50,089	Ref	7.34	Ref	2,214	9,489	3,678	Absolutely dominated
Brand dabigatran	$52,961	$2,872	7.35	0.01	2,167	12,125		Absolutely dominated
Brand dabigatran	$52,961	$2,872	7.35	0.01	2,167	8,721	3,404	Absolutely dominated
Generic dabigatran (F = 0.9)	$49,443	−$646	7.37	0.03	2,203	11,391		Dominant^a
Generic dabigatran (F = 0.9)	$49,443	−$646	7.37	0.03	2,203	8,207	3,184	Dominant^a

F, bioavailability ratio vs. reference brand; QALY, quality‐adjusted life years.

Dominant implies both lower costs and higher effectiveness (QALYs).